SGRL · NSE
Shree Ganesh Remedies Limited
₹697.75
+2.88% (+₹19.55)
Prev. close
₹678.2
Volume
18,488
Delivery %
61.0%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Shree Ganesh Remedies Limited
Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India and internationally. The company offers anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, antifungal, antihistamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder, ophthalmic, opioid, and veterinary API intermediates. It also provides fine and specialty chemicals, such as agro-chemicals, electronics, flavor and fragrance, life-sciences, and polymer chemicals, as well as other specialty chemicals. In addition, the company offers customized chemistry and manufacturing; assets and infrastructure; and customized processes of pharmaceutical chemicals. It also exports its products. The company serves life sciences, flavor and fragrance, polymer industries, electronics, and agro chemicals markets. Shree Ganesh Remedies Limited was incorporated in 1995 and is headquartered in Ankleshwar, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Chandulal Manubhai Kothia
Headquarters
Ankleshwar
Employees
224
Website
ganeshremedies.comExchange
View on NSE ↗Key stats
Market cap
₹895.74 Cr
P/E ratio (TTM)
58.1
EPS (TTM)
₹12.00
Beta (5Y monthly)
0.49
Shares float
31.00 L
EPS · quarter ended Jun 2026
₹0.87
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹49.08 Cr | ₹71.29 Cr | ₹90.22 Cr | ₹124.80 Cr | ₹106.50 Cr | ₹108.09 Cr | |
| EBITDA | ₹15.74 Cr | ₹21.49 Cr | ₹26.42 Cr | ₹44.82 Cr | ₹42.85 Cr | ₹37.89 Cr |
| ₹9.75 Cr | ₹13.40 Cr | ₹17.02 Cr | ₹28.11 Cr | ₹23.07 Cr | ₹17.76 Cr | |
| Diluted EPS | ₹9.75 | ₹11.16 | ₹14.01 | ₹22.34 | ₹17.96 | ₹13.83 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹77.02 Cr | ₹143.83 Cr | ₹170.94 Cr | ₹191.94 Cr | ₹207.69 Cr | |
| — | — | ₹33.51 Cr | ₹36.45 Cr | ₹38.38 Cr | ₹30.81 Cr | |
| Stockholders' equity | — | ₹61.57 Cr | ₹88.94 Cr | ₹122.10 Cr | ₹145.16 Cr | ₹162.97 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹17.01 Cr | ₹30.45 Cr | ₹30.66 Cr | ₹23.74 Cr | |
| Investing cash flow | — | — | ₹-53.57 Cr | ₹-33.01 Cr | ₹-35.66 Cr | ₹-9.89 Cr |
| — | — | ₹41.33 Cr | ₹9.84 Cr | ₹-1.09 Cr | ₹-11.70 Cr | |
| Capital expenditure | — | — | ₹-51.58 Cr | ₹-31.14 Cr | ₹-23.20 Cr | ₹-16.60 Cr |
| End cash position | — | — | ₹8.65 Cr | ₹15.85 Cr | ₹9.95 Cr | ₹13.40 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Shree Ganesh Remedies Limited | ₹832.71 Cr | ₹678.2 | 53.9 | 5.11 | 10.9% | 0.19 | +1.5% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index